Statista, a global data company that publishes insights for 170 industries, projects four cancer therapies will be among the top 10 best-selling pharmaceutical products in the U.S. this year.
The company projects Merck’s cancer drug Keytruda will earn $12.7 billion in U.S. revenue in 2026 — nearly twice that of the second top-selling medication, according to data shared March 9 with Becker’s.
Here are the medications Statista projects will be the 10 best-selling U.S. pharmaceutical products in 2026:
1. Keytruda — $12.7 billion
Manufacturer: Merck
FDA-approved for about a dozen cancers, including non-small cell lung cancer and melanoma
2. Biktarvy — $8.2 billion
Manufacturer: Gilead Sciences
FDA-approved as an HIV-1 treatment
3. Eliquis — $7.8 billion
Manufacturer: BMS
FDA-approved as a blood thinner medicine to reduce blood clotting
4. Imbruvica — $6.7 billion
Manufacturer: AbbVie
FDA-approved for several blood cancers and chronic graft-versus-host disease
5. Dupixent — $6.4 billion
Manufacturer: Sanofi
FDA-approved for nine chronic inflammatory conditions, including chronic obstructive pulmonary disease
6. Opdivo — $6.1 billion
Manufacturer: BMS
FDA-approved for more than a dozen cancers, including melanoma and renal cell carcinoma
7. Ozempic — $6 billion
Manufacturer: Novo Nordisk
FDA-approved for Type 2 diabetes, cardiovascular disease and kidney disease
8. Trikafta — $6 billion
Manufacturer: Vertex
FDA-approved for cystic fibrosis
9. Ocrevus — $5.9 billion
Manufacturer: Roche
FDA-approved for multiple sclerosis
10. Ibrance — $5.9 billion
Manufacturer: Pfizer
FDA-approved for breast cancer
The post 10 drugs expected to lead US sales in 2026 appeared first on Becker's Hospital Review | Healthcare News & Analysis.
Source: Read Original Article
